Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

Inclusion Criteria:

* Patient aged from 45 to 80 years old
* Life expectancy \>10 years at the inclusion time
* Patient diagnosed with an intermediate-risk prostate cancer, defined by:

  * A T1c or T2a clinical stage
  * A unique cancer focus of Gleason (3+4) (Grade Group 2). In addition to the index lesion intended for treatment, the presence of additional microfoci \< 10mm on mpMRI, for which biopsies present no evidence of cancer or a Gleason score of 3+3, is accepted
  * A PSA level \<20 ng/mL
* Cancer focus identified on a multiparametric MRI of the prostate no more than 3 months before inclusion
* Confirmation of the suspicion of cancer identified on the MRI with transrectal or transperineal targeted and systematic biopsies performed with the KOELIS TRINITY system (no more than 3 months before inclusion)
* Patient suitable for IV sedation or general anesthesia and focal microwave ablation
* No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up
* Known coagulopathy or bleeding disorders are controlled
* Free, informed and written consent, dated and signed before the enrollment and before any exam required by the trial
* Patient affiliated to social security regimen or beneficiary of such regimen for local regions

Exclusion Criteria:

* Past medical history of prostate surgery
* Past medical history of radiotherapy or pelvic trauma
* Past medical history of acute prostatitis
* Presently taking hormonal manipulation or androgen supplements.
* Past medical history of cancer in the 5 previous years, excluding a non-metastatic basal cell carcinoma of the skin
* Severe BPH-related urinary tract symptoms, defined by an IPSS score \>18
* Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit
* Contraindications for MRI exam
* Extracapsular cancer extension or seminal vesicles or pelvic lymph node invasion suspected on prostate MRI
* Presence of two or more clinically significant cancer foci in the inclusion biopsy exam
* Presence of a clinically significant cancer with a Gleason score ≥8 (Grade Group ≥4)
* Tumor largest axis \>15 mm on the prostate MRI
* Distance between the cancer focus and the apex \<5 mm on the prostate MRI
* Distance between the cancer focus and the rectum \<5 mm on the prostate MRI
* Patient already participating in an interventional clinical trial
* Patient protected by law